Natera agreed to acquire Foresight Diagnostics, integrating the firm’s PhaseED-Seq phased-variant technology to enhance Natera’s Signatera MRD platform and accelerate lymphoma and solid-tumor applications. The deal structure includes $275 million up front and up to $175 million in milestone payments tied to revenue and reimbursement. Natera said the transaction will deepen sensitivity for minimal residual disease detection and speed clinical adoption in lymphoma, where Foresight already has research momentum. The combined offering aims to strengthen commercial differentiation for personalized MRD testing in pharma trials and clinical care.